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ABSTRACT
Introduction: Low rates of accrual of AfricanAmerican (AA) patients with cancer to therapeutic
clinical trials (CTs) represent a serious and modifiable
racial disparity in healthcare that impedes the
development of promising cancer therapies.
Suboptimal physician–patient consultation
communication is a barrier to the accrual of patients
with cancer of any race, but communication difficulties
are compounded with AA patients. Providing tailored
health messages (THM) to AA patients and their
physician about CTs has the potential to improve
communication, lower barriers to accrual and
ameliorate health disparities.
Objective: (1) Demonstrate the efficacy of THM to
increase patient activation as measured by direct
observation. (2) Demonstrate the efficacy of THM to
improve patient outcomes associated with barriers to
AA participation. (3) Explore associations among
preconsultation levels of: (A) trust in medical
researchers, (B) knowledge and attitudes towards CTs,
(C) patient-family member congruence in decisionmaking, and (D) involvement/information preferences,
and group assignment.
Methods and analysis: First, using established
methods, we will develop THM materials. Second, the
efficacy of the intervention is determined in a 2 by 2
factorial randomised controlled trial to test the
effectiveness of (1) providing 357 AA patients with
cancer with THM with 2 different ‘depths’ of tailoring
and (2) either providing feedback to oncologists about
the patients’ trial THM or not. The primary analysis
compares patient engaged communication in 4 groups
preconsultation and postconsultation.
Ethics and dissemination: This study was approved
by the Virginia Commonwealth University Institutional
Review Board. To facilitate use of the THM intervention
in diverse settings, we will convene ‘user groups’ at 3
major US cancer centres. To facilitate dissemination,

Strengths and limitations of this study
▪ This study is designed to overcome significant
health disparities by improving AfricanAmerican–oncologist communication about
therapeutic clinical trials.
▪ This study will extend our knowledge of tailored
health messaging.
▪ This study is a randomised controlled trial of tailored health messaging in a novel setting, cancer
clinical trial communication.
▪ We have limited capacity to assess the differential efficacy of the intervention between phase I,
II and III clinical trials.
▪ This study is being conducted at one academic
cancer centre, thus communication issues particular to the community oncology setting will
not be assessed.
we will post all materials and the implementation guide
in publicly available locations.
Trial registration number: NCT02356549.

INTRODUCTION
The cancer mortality rate in the USA is 33%
higher for African-Americans (AA) than for
white Americans and AA have the lowest
5-year survival rates when compared with all
other racial groups.1 In the USA, the
National Cancer Institute, the American
Cancer Society and the American Society for
Clinical Oncology have recognised and
reported the unequal burden of cancer in
AA patients and their low representation in
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clinical trials (CTs). The effectiveness of this translational process is greatly dependent on the number and
representativeness of participants enrolled in trials, yet
<5% of all adult patients with cancer enter CTs and even
lower participation rates are reported in minority populations, including AA.2–4
Inequitable participation in state of the art cancer
care contributes to health disparities in cancer mortality
and survival between AA and whites.5 6 Speciﬁcally, low
representation of AA patients in CTs compromises the
generalisability and external validity of trial results,7 8
and may fail to identify important positive or negative
treatment effects among under-represented populations.9 10 Barriers to minority patients’ participation in
CTs include systemic factors,11 12 such as strict exclusion
criteria,11 which limit AA opportunities to participate.12
However, studies suggest that racial differences in
patient barriers to participation are due in part to nonclinical factors related to poor trial information,13 14 mistrust of medical research,15 family pressures12 and poor
communication with physicians.5 11 16 Thus, high-quality
physician–patient communication is key to increasing
the active engagement of AA patients in decision-making
about CTs. Yet, there is mounting evidence about the
communication challenges present in treatment discussions,16–31 including CTs that are compounded with AA
patients.32 33 Racial disparities in communication could
lead to less informed decisions34 and lower trust in physicians.34 As such, there is a critical need to develop
communication interventions to modify barriers to
recruitment and hopefully ameliorate health disparities
and optimise the beneﬁts of CTs.5 6 11 35
One communication method that has demonstrated
efﬁcacy to promote patient activation (characterised by
asking questions, expressing concerns and being assertive) in consultation communication is providing tailored
health messages (THM).36 THM increase the relevance
of health information by targeting individuals’ personalised needs based on a rigorous assessment of their
characteristics and preferences37 and have been successfully used to promote AA cancer screening behaviours.38
The process of tailoring health messages involves collecting data (usually by way of a comprehensive survey)
about the receiver’s needs and preferences and then
preparing individually customised materials (eg, print
materials or online tools) that meet these needs.
Evidence indicates that THM interventions are effective;39 however, research is still needed to explicitly
explore factors that most contribute to their success.
The exact number of variables needed and the level and
intensity of tailoring (depth of tailoring) required to
achieve research goals is not known. Physician–patient
communication is known to be a dynamic process; yet,
no studies, to the best of our knowledge, have explored
the impact of involving patients and physicians in THM
interventions that target cancer CT consultations. The
goal of this study is to test the efﬁcacy of (1) providing
AA patients with cancer with tailored CT messages with
2

two different depths of tailoring and (2) either providing feedback to oncologists about the patients’ tailored
CT messages or not.
To the best of our knowledge, this is the ﬁrst randomised controlled trial (RCT) which assesses the efﬁcacy
of a THM intervention on AA patients with cancer (1)
active communication in CT consultations as measured
by objective coding of consultation audio recordings, (2)
self-reported barriers to joining CTs, and (3) satisfaction
and decision-related outcomes.
METHODS AND ANALYSIS
Study design
This study is an RCT using a two by two factorial design.
Equal numbers of participants are randomly assigned to
one of four intervention groups.
This study follows CONSORT guidelines (ﬁgure 1).40
Group 1 (n=89): shallow tailoring—Patients receive
THMs based only on demographic and disease information extracted from their electronic medical records
(EMR). These variables include (1) demographic information: age, income, education and health insurance
status; (2) disease variables: cancer type and severity;
and (3) trial variables: phase of trial being offered and
prior trial participation.
Group 2 (n=89): shallow tailoring+physician involvement—
Patients receive THMs based on EMR data, and their
physicians receive a summary of the THMs that are provided to the patients.
Group 3 (n=89): deep tailoring—Patients receive THMs
based on EMR data as well as data derived from a survey
that patients completed on enrolment.
Group 4 (n=89): deep tailoring+physician involvement—
Patients receive THMs based on EMR and survey data,
and their physicians receive a summary of the THMs
that are provided to the patients (ﬁgure 2).
Intervention
Tailored message development
THMs were developed using guidelines presented in the
health communication literature.41 42 Many THM interventions are based on the input of data collected by
means of a comprehensive survey to produce messages
that are matched to an individual recipient’s needs and
preferences. However, patient data to inform tailoring
can also be generated by accessing patient data through
EMR.37 As we intend to explore the impact of different
‘depths’ of tailoring, we use both comprehensive surveys
and EMR data to generate patient data to produce two
types of THM.
The ﬁrst step to develop the THMs is to generate
patient data to develop tailored messages about CTs. To
achieve this, we extract patient demographic and disease
variables and information about their CT experience
from patients’ EMR and use these data to generate a
‘shallow’ level of tailoring. These data include: (1)
demographic information such as age, education level,
Brown RF, et al. BMJ Open 2016;6:e012864. doi:10.1136/bmjopen-2016-012864
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Figure 1 Consort diagram. EMR, electronic medical records.

income; (2) health information such as disease site and
severity; and (3) trial information such as the phase of
trial offered and previous trial involvement.
Tailoring survey
We use standardised, psychometrically sound measures
to gather information about patients, including their
levels of trust in medical research and use these data,
augmented by their EMR data, to develop a ‘deeper’
level of THM. These measures are listed in box 1.
Participants randomised to deep tailoring complete
these measures as part of the tailoring survey in order to
develop THM. We include these measures in patient
assessment surveys for the other intervention groups.
Knowledge/attitudes towards trials and health literacy
Brown RF, et al. BMJ Open 2016;6:e012864. doi:10.1136/bmjopen-2016-012864

will be assessed as potential confounding variables. The
other variables are assessed as outcomes.
The second step is to develop the three necessary
components to deliver tailored messages: (1) the design
template; (2) message concepts and (3) tailoring algorithms. We use the Michigan Tailoring System (MTS)
software program to support the development of the
three components. The MTS is an open-source software
toolkit which can create THM for a variety of delivery
modes, such as print, web and mobile devices.50 We ﬁrst
developed a design template to visualise the message
layout, with the goal of producing a two-page, doublesided brochure for participating patients and a one-page
summary of the brochure content for the physicians.
The design template shows where each message will
3
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Figure 2 A 2×2 Factorial design. EMR, electronic medical
records.

Box 1 Standardised measures to be used for survey
tailoring
Knowledge/attitudes towards clinical trials43
Health literacy44
Trust in medical researchers45
Trust in physician46
Communication self-efficacy47
Information preferences48
Decision involvement preferences49

appear on the page, how blocks of messages relate to
each other and information about the content of each
block of messages.37 Next, we developed message concepts, for example, shallow versus deep messages concerning medical mistrust, which are the detailed ideas
about the content of the THMs. Speciﬁc concepts are
created for each potential message.37 Then, we created a
set of tailoring algorithms, which are decision rules that
guide every judgement about which THMs each patient
will receive37 (see ﬁgure 3 below for an example).
Implementing and assessing the intervention
Data from study participants in groups 1 and 2, who are
randomised to receive THMs based on their EMR data
alone, are entered into the MTS system and their brochures are prepared. These brochures are mailed 1 day
after participants have assented to the study. To standardise our data collection across all groups, participants
complete the survey described above in box 1. One
week before their scheduled appointment to discuss a
CT with their physician, a study research assistant (RA)
calls the participant to administer the survey over the
telephone. If a participant does not have a telephone,
we mail the survey along with a prepaid return envelope

Figure 3 Decision rule example. Q5 trust in physicians.
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and ask the participant to complete and return the
survey within a 24-hour time frame.
Study participants randomised to groups 3 and 4, who
are randomised to receive THMs based on both their
EMR data and survey responses, complete the survey
within 1 week of the participant’s scheduled appointment with their physician to discuss a CT. The study RAs
call participants to complete the survey over the telephone, with follow-up by mail, as described above for
groups 1 and 2, if the participant cannot be reached by
telephone. Once the survey responses are received, they
are entered into the MTS software along with patient
EMR data, and the personalised THMs are instantly generated and colour printed in the format described
above. The brochures are mailed to participants to read
and participants are encouraged to bring their THM
brochure to their consultation to discuss a CT.
Prior to the consultation, physicians of patients randomised to groups 2 and 4 receive a printed summary of
each patient’s THMs in the patient’s notes.
When participants arrive for their appointed consultation, they are met by a study RA. The RA gains written
informed consent (see recruitment plan below) and
remains present to audio record the consultation. The
RA places a digital audiorecorder in the consulting
room and then leaves for the remainder of the consultation. The RA collects the audiorecorder at the conclusion of the consultation. At this time, participants
complete a second brief survey asking about the tailored
message brochure. One family member/caregiver of
consented participants is also recruited or identiﬁed for
recruitment at this time. Consented family member/
caregivers are asked to complete the Communication
Assessment Tool for Patients and Families (CCAT-PF), a
measure of perceived congruence over the treatment
decision (see recruitment plan below).
If a CT was not discussed the participants’ involvement
in the study is complete and their data and the audio
recordings are stored along with all other participant
data. If a CT was discussed during the consultation,
patients are asked to complete a third survey to assess
their immediate, postconsultation impressions of the CT
conversation. At this time, the RA identiﬁes a convenient
time for the patient to receive a follow-up telephone call
at ∼1 month after the consultation visit to complete a
ﬁnal survey. At the appointed time, the RA will call to
administer this postconsultation evaluation survey.
Patients who do not have a telephone will receive the
questionnaire via mail 1 month after the visit along with
a prepaid return envelope. These participants will be
asked to complete and return the survey within a
24-hour time frame. We chose to collect data 1 month
after the consultation in order to ensure that patients
have had time to (1) make a treatment decision and (2)
have started cancer treatment.
Fidelity plan: We have developed a comprehensive ﬁdelity plan. In summary, we will (1) conduct regular checks
to
ensure
that
participants
complete
the
Brown RF, et al. BMJ Open 2016;6:e012864. doi:10.1136/bmjopen-2016-012864
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phone-administered surveys, (2) use a preconsultation
questionnaire to monitor whether participants redeive
and understand the THM brochure, (3) conduct
regular interviews with physicians in groups 2 and 4 to
ascertain that they are reading the THM summary.
Setting
This study is being conducted at the Massey Cancer
Center (MCC), a National Cancer Institute designated
centre in Richmond, Virginia, USA. MCC is a safety net
hospital that provides inpatient and outpatient services
to patients with cancer from a broad catchment area.
MCC has a diverse patient population and thus consistently recruits minority patients to trials, mostly AA, at
rates above the national average. Thirty-six oncologists
have been recruited from the surgical, hematology and
radiation oncology services between June 2015 and
December 2015.
Sample and recruitment
Physician identification and accrual
There are 40 oncologists currently practising at MCC
who are eligible to participate in this communication
study. Physicians who recruit AA patients to CTs at MCC
are eligible to participate. To inform oncologists about
the study, a detailed description is presented at clinical
conferences and individual discussions are held with
physicians as needed. Written consent to participate is
obtained at these meetings.
Patient/family member identification and recruitment
Patient identification and recruitment
This study will recruit 357 patients, which is a feasible
number given the patient resources available at MCC.
This study recruits AA patients who are eligible for a
phase I, II or III therapeutic CT, regardless of whether
they join the therapeutic trial or not. Eligible patients
have a cancer diagnosis, self-identify as AA, are eligible
for a therapeutic phase I, II or III CT at MCC, are able
to provide informed consent, and are 21 years of age or
older.
Study personnel use the Virginia Commonwealth
University Health system EMR database to identify all
potentially eligible patients with cancer.51 52 RAs attend
weekly multidisciplinary disease team meetings where
patient eligibility for CTs is discussed. Once therapeutic
trial eligible patients have been identiﬁed, RAs obtain
physician approval to approach each patient.
The steps involved in patient recruitment are as
follows:
Step 1: The RA sends the identiﬁed patient a letter
that provides a brief description of this study and indicates that they will call the patient within 1 week to
discuss the patient’s possible participation. Step 2: The
RA calls the patient to inform them about the purpose
and requirements of the study and asks him/her to consider participation. Each patient who verbally assents is
then randomised to one of the four study groups. Step 3:
Brown RF, et al. BMJ Open 2016;6:e012864. doi:10.1136/bmjopen-2016-012864

On the day of the trial consultation, patients receive an
information sheet and are asked to provide written
consent. (see online supplementary ﬁle).
Family member recruitment
We also recruit one family member/caregiver of each
participating patient in order to assess the level of congruence between the patient and their family member
over the eventual treatment decision. Consented
patients will not be excluded from this study if their
family member declines to participate. We recruit family
members/caregivers who are nominated by the consented patient as important to the trial decision. Within
1 week of the consultation family members complete a
measure of decisional congruence, the CCAT-PF53 in
person or over the phone.
Randomisation
The randomisation is conducted off site according to
protocols developed by the study statistician. We make
use of the randomisation procedures in SAS/STAT. The
allocation sequences are stored in a computer ﬁle and
are unknown to the researchers until the patient is randomised. Block randomisation is used to minimise large
imbalances between the four groups. Patients are
unaware of the treatment allocation: however, it is not
possible to blind oncologists to their patients’ treatment
allocation. The raters who code audio recordings of the
consultations are not aware of the patients’ group
allocation.
Study aims and hypotheses
The speciﬁc aims and study hypotheses are listed below.
Aim 1: Demonstrate the efﬁcacy of the THM intervention to increase patient activation as measured by coding
consultation audio recordings using the Street Patient
Activation Coding system.50
H1: Group 3 will be more active communicators than
group 1.
H2: Group 2 will be more active communicators than
group 1.
H3: Group 4 will be more active communicators than
group 3.
Aim 2: Demonstrate the efﬁcacy of the THM to
improve patient outcomes.
H4: Group 3 will report higher scores on: trust in their
physician, preference achievement, communication selfefﬁcacy, consultation satisfaction and decision outcomes
than group 1.
H5: Group 2 will report higher scores than group 1 on
the same group of outcomes as H4.
H6: Group 4 will report higher scores than group 3 on
the same group of outcomes as H4 and H5.
Aim 3: Explore the association between preconsultation levels of (1) trust in medical researchers, (2) knowledge and attitudes towards CTs, (3) patient family
member congruence, and (4) involvement/information
preferences and group assignment.
5
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Study measures
Data collection: All patient identiﬁers, questionnaire
responses and digital audiorecrdings will be stored on a
HIPAA compliant server and will only be available to
study staff.
Data extraction from EMR
Postvisit, we will extract trial data from the EMR including whether the patient enrolled and if not, whether
this was due to systemic factors such as insurance status.
Consultation audio recording
The CT consultation discussions are audio recorded and
subsequently coded using the Street Patient Activation
Coding system54 to gather data about patient–physician
communication, including the level of patient activation
in the consultation.
Consultation coding for patient activation
The primary outcome variable used for this study will be
patient activation as measured by the Street Patient
Activation Coding system.54 The coding system will be
used to code for three patient participation behaviours
(asking questions, expressions of concern and verbally
assertive responses) and two physician patient-centered
responses ( partnership building and supportive talk).
The Street Coding system has been used in multiple
studies to assess patient activation33 55 and has been
used successfully as an outcome variable.56 Once coding
is completed, a composite score is calculated and
entered and stored in an Excel database that is exported
to SAS for analysis.
Measures
Questionnaire data
Physician demographics
Participating clinicians provide information about their
age, gender, race, specialty, years of practice and years

recruiting patients to phase I, II and III CTs at the time
when they are recruited to the communication study.
Patient questionnaires
Patients complete questionnaires prior to their consultation, immediately postconsultation and 1 month after
their consultation. All measures have been previously
published and are standardised and validated scales.
Table 1 below provides the details of each of the scales
and an administration schedule.
Power analysis and sample size calculation
We computed power to detect cross-sectional group differences on the primary outcome, patient activation
using 2×2 analysis of covariance (ANCOVA) with two covariates which is the least powered scenario in the proposed analytic plan. Using previous ﬁndings reporting a
mean count of active patient utterances from the Street
Coding system54 used in a sample of African-American
patients of 5.9, SD=5.5, we compute sample size needed
to detect a ½ SD difference between groups, which represents an effect size of 0.223. Power is 0.90 with an N=357.
Data analyses
All analyses will be conducted as intention-to-treat given
available data including outcomes extracted from
medical records even if the participant does not complete the full research protocol, for example, becomes
too ill. We will conduct post hoc exploratory analyses to
examine whether the intervention was more effective for
some groups than others, for example, by age and
gender.
Aim 1
Once descriptive (univariate) analyses are completed,
we will use bivariate statistics and means testing for
hypotheses testing. Bivariate analyses will ﬁrst be used to
examine depth of tailoring, physician involvement and
patient activation. ANCOVA will be used to evaluate the

Table 1 Questionnaires and assessment tools used in the study Questionnaire content and schedule—preclinical and
postclinical trials consultation
Measures

Preconsultation
43

Knowledge/attitudes towards clinical trials
Trust in medical researchers45
Trust in physician46
Information preferences48
Decision involvement preferences49
Communication self efficacy47
Patient/family communication congruence53
Health literacy44
Understanding of clinical trials57
Decisional conflict58
Satisfaction with the decision59
Satisfaction with consultation communicationn60
Decision regret61
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✓
✓
✓
✓
✓
✓
✓
✓

Immediate post
✓
✓
✓
✓
✓
✓
✓

One month post
✓
✓
✓

✓
✓
✓
✓
✓
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main effect of depth of tailoring, the main effect of
physician involvement and possible interactions between
depth of tailoring and physician involvement on patient
activation.
Aim 2
Bivariate analyses will ﬁrst be used to examine depth of
tailoring, physician involvement and trust in their physician, levels of achievement of information and involvement preferences, levels of communication self-efﬁcacy,
satisfaction with the consultation communication, satisfaction with their decision, levels of decisional conﬂict
and levels of decision regret. Multivariate ANCOVA
(MANCOVA) will be used to evaluate the main effect of
depth of tailoring, the main effect of physician involvement and possible interactions between depth of tailoring and physician involvement on all dependent
variables.
Aim 3
Bivariate analyses will ﬁrst be used to examine depth of
tailoring, physician involvement and trust in medical
researchers, knowledge and attitudes towards CTs,
patient/family member congruence and involvement/
information preferences and health literacy. MANCOVA
will be used to evaluate the main effect of depth of tailoring, the main effect of physician involvement and possible interactions between depth of tailoring and
physician involvement on patient activation using each
of these characteristics as well as phase of trial as covariates. Repeated measures MANCOVA will be constructed
similarly to the proposed MANCOVA to examine stability
and/or change in characteristics assessed over time (eg,
decisional conﬂict).
Expected achievement
Using established methods of THM, we are directly
intervening in the physician–AA patient CT consultation
communication process to increase patient activation in
the consultation to potentially improve a range of relevant patient outcomes. Since we are extending the use
of the THM intervention, by assessing depth of tailoring
and physician involvement in the intervention, we anticipate that our results will inform scientiﬁc knowledge
and inﬂuence optimal use of THM in multiple clinical
settings.
DISCUSSION
Therapeutic CTs test the efﬁcacy of newly emerging
cancer treatments, yet few patients with cancer participate, thus slowing the progress of new treatments and
their implementation to ﬁght cancer. African-American
patients with cancer are among the least likely to be
offered to join a CT and among the least likely to join a
trial if asked. Ineffective consultation communication
has been identiﬁed as a signiﬁcant factor contributing to
AA patient refusal to join a trial. We suggest that using
Brown RF, et al. BMJ Open 2016;6:e012864. doi:10.1136/bmjopen-2016-012864

THM coupled with physician involvement in the intervention process has the potential to assist AA patients to
be more engaged and active communicators, which in
turn may help overcome barriers to trial enrolment and
improve signiﬁcant patient outcomes.
THM increase the relevance of health information by
targeting individuals’ personalised needs based on a
rigorous assessment of their characteristics and preferences.37 No studies to date have explored the impact of
providing tailored CT information to promote active AA
participation in CT consultations. Thus, this project
extends the use of THM into a novel clinical context with
the potential to reduce health disparities associated with
AA recruitment to cancer CTs. This study is innovative in
that we will test the impact of shallow versus deep tailoring to provide new information about the depth of tailoring required to increase patient activation. Further, in
spite of the dynamic nature of consultation communication, no studies have explored the additional impact of
involving patients and physicians in THM interventions.
These data can potentially be used to inform and impact
optimal methods for using tailored health messaging.
There are three main limitations to this study. First, our
own data suggest that communication challenges differ
between phases I, II and III trials. For example, physicians may be more paternalistic with patients facing a
phase I CT than those facing a phase III trial.21 Our
sample size does not allow us to stratify the randomisation by trial phase as this would almost triple the sample
required. Second, we will recruit participants from MCC,
a safety net hospital. However, we will not cover communication issues particular to the community oncology
setting. Third, physician training to use the patients’
THM summary will not be provided. Future research
could usefully add and assess such a training component.
ETHICS AND DISSEMINATION PLAN
The study is registered at Clinical trials.gov, identiﬁer—
NCT02356549.
Patient recruitment started in April 2016 and is
expected to close in June 2018.
This program is designed to be ‘turnkey’, in that all of
the core processes needed to implement the program
will be ﬁnalized on project completion and readily available at no cost and can be downloaded from our own
local websites and other national websites. To facilitate
use of the THM intervention in diverse settings, we will
convene ‘user groups’ at three major US cancer centres.
Input from these user groups will be used to develop an
implementation guide. To facilitate dissemination, we
will post all materials and the implementation guide in
publicly available locations. We will also attend scientiﬁc
meetings and publish manuscripts that detail the study.
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